Already a leader in the treatment of prostate and breast cancer,Pfizer,the world's largest pharmaceutical company,has further enlarged its oncology portfolio by completing its acquisition of Array BioPharma,Inc.,the company announced on 30 July 2019.This will advance breakthrough science for the discovery,development and commercialisation of targeted small molecule medicines to treat cancer and other diseases of high unmet need,Pfizer said.*
Array's portfolio included the approved combined use of BRAFTOVI (R) and MEKTOVI (R) for the treatment of two forms of unresectable or metastatic melanoma skin cancer,with significant potential for long-term growth with expansion into additional areas of unmet need.The combination is also being investigated as a potential first-in-class combination for the treatment of BRAF-mutant metastatic colorectal cancer (mCRC),based on interim results the company feels are compelling from the pivotal Phase 3 BEACON trial,according to Pfizer.They believe this application has industry-leading potential.*
Pfizer says it will maintain Array's operations in Cambridge,Massachusetts;Morrisville,North Carolina;and Boulder,Colorado.Array is now a wholly-owned subsidiary of the New York-based pharma titan.The all-cash deal had a value of around 11.4 billion dollars.*
Pfizer Inc (PFE)
Showing posts with label colorectal cancer. Show all posts
Showing posts with label colorectal cancer. Show all posts
Monday, August 26, 2019
Thursday, July 5, 2012
USC Norris Doctors Advance Cancer Research
A number of physician researchers from the USC Norris Comprehensive Cancer Center in Los Angeles were collaborators on more than 70 research projects presented at the 2012 annual meeting of the American Society of Clinical Oncology.About 30,000 oncologists from around the world attend the meeting to review the latest developments in their field.Advances in the treatment of cancer and patient care were set forth in more than 4500 abstracts presented or published at the gathering.Topics of the papers included targeted therapy;clinical trial results for a wide rage of cancers;and patient quality of life.The meeting took place at McCormick Place in Chicago from June 1-5.
One of the more promising studies presented was collaborated on by Heinz-Josef Lenz,associate director for clinical research and co-leader of the gastrointestinal cancers program at the USC Norris CCC.It was an international phase III trial of regorafenib,a candidate drug that has been found to significantly improve overall survival in metastatic colorectal cancer patients who are unresponsive to other approved therapies.It is believed that the drug,pending FDA approval,will raise the standard of care for these patients.
Regorafenib is an oral drug developed by Bayer AG.Its stock trades on the OTC pink sheets in the U.S. under the ticker symbol BAYRY.The company is well known as the maker of Bayer aspirin products.Indeed,Bayer AG was the first producer of aspirin tablets.
One of the more promising studies presented was collaborated on by Heinz-Josef Lenz,associate director for clinical research and co-leader of the gastrointestinal cancers program at the USC Norris CCC.It was an international phase III trial of regorafenib,a candidate drug that has been found to significantly improve overall survival in metastatic colorectal cancer patients who are unresponsive to other approved therapies.It is believed that the drug,pending FDA approval,will raise the standard of care for these patients.
Regorafenib is an oral drug developed by Bayer AG.Its stock trades on the OTC pink sheets in the U.S. under the ticker symbol BAYRY.The company is well known as the maker of Bayer aspirin products.Indeed,Bayer AG was the first producer of aspirin tablets.
Subscribe to:
Posts (Atom)